W
Wade J. Sexton
Researcher at University of South Florida
Publications - 214
Citations - 5692
Wade J. Sexton is an academic researcher from University of South Florida. The author has contributed to research in topics: Bladder cancer & Medicine. The author has an hindex of 30, co-authored 171 publications receiving 4755 citations. Previous affiliations of Wade J. Sexton include Dana Corporation & Uniformed Services University of the Health Sciences.
Papers
More filters
Journal ArticleDOI
Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial
Naomi B. Haas,Judith Manola,Robert G. Uzzo,Keith T. Flaherty,Christopher G. Wood,Christopher J. Kane,Michael A.S. Jewett,Janice P. Dutcher,Michael B. Atkins,Michael R. Pins,G. Wilding,David Cella,Lynne I. Wagner,Surena F. Matin,Timothy M. Kuzel,Wade J. Sexton,Yu-Ning Wong,Toni K. Choueiri,Roberto Pili,Igor Puzanov,Manish Kohli,Walter M. Stadler,Michael A. Carducci,Robert Coomes,Robert S. DiPaola +24 more
TL;DR: Sunitinib and sorafenib, two oral anti-angiogenic agents that are effective in advanced renal-cell carcinoma, are tested in patients with resected local disease at high risk for recurrence in a double-blind, placebo-controlled, randomised, phase 3 trial.
Journal ArticleDOI
Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical Prostatectomy
Christopher L. Amling,Robert H. Riffenburgh,Leon Sun,Judd W. Moul,Raymond S. Lance,Leo Kusuda,Wade J. Sexton,Douglas W. Soderdahl,Timothy F. Donahue,John P. Foley,Andrew Chung,David G. McLeod +11 more
TL;DR: Findings support the hypothesis that obesity is associated with progression of latent to clinically significant prostate cancer (PC) and suggest that BMI may account, in part, for the racial variability in PC risk.
Journal ArticleDOI
Bladder cancer. Clinical practice guidelines in oncology.
Peter E. Clark,Neeraj Agarwal,Matthew C. Biagioli,Mario A. Eisenberger,Richard E. Greenberg,Harry W. Herr,Brant A. Inman,Deborah A. Kuban,Timothy M. Kuzel,Subodh M. Lele,Jeffrey M. Michalski,Lance C. Pagliaro,Sumanta K. Pal,Anthony Patterson,Elizabeth R. Plimack,Kamal S. Pohar,Michael P. Porter,Jerome P. Richie,Wade J. Sexton,William U. Shipley,Eric J. Small,Philippe E. Spiess,Donald L. Trump,Geoffrey Wile,Timothy G. Wilson,Mary A. Dwyer,Maria Ho +26 more
TL;DR: Experts believe that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients at all stages of disease.
Journal ArticleDOI
Pretreatment Total Testosterone Level Predicts Pathological Stage in Patients With Localized Prostate Cancer Treated With Radical Prostatectomy
Jason C. Massengill,Leon Sun,Judd W. Moul,Hongyu Wu,David G. McLeod,Christopher L. Amling,Raymond S. Lance,John P. Foley,Wade J. Sexton,Leo Kusuda,Andrew Chung,Douglas W. Soderdahl,Timothy R. Donahue +12 more
TL;DR: Pretreatment total testosterone was an independent predictor of extraprostatic disease in patients with localized prostate cancer, and low testosterone was not predictive of biochemical recurrence, although trends observed dictate study in larger cohorts with mature followup.
Journal ArticleDOI
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Judd W. Moul,Judd W. Moul,Hongyu Wu,Leon Sun,David G. McLeod,Christopher L. Amling,Timothy R. Donahue,Leo Kusuda,Wade J. Sexton,Keith J. O’Reilly,Javier Hernandez,Andrew Chung,Douglas W. Soderdahl +12 more
TL;DR: The retrospective observational multicenter database analysis demonstrated that early HT administered for PSAR after prior RP was an independent predictor of delayed clinical metastases only for high-risk cases at the current followup.